Josh D. Woolley has a warning for the world of psychedelic science: don't assume the obvious is real. In a new paper published Sept. 16 in JAMA Psychiatry, the UC San Francisco psychiatrist and his colleagues at UC San Diego and Stanford University take on one of the trickiest problems in medical research — proving that mind-altering drugs actually work.
The trouble starts with "masking," the gold standard of clinical trials. Masking means neither the patient nor the researchers know who got the real medicine and who got a fake, called a placebo. This prevents people's hopes from skewing the results. But psychedelics are so distinctive that almost everyone can tell when they've taken one. Patients who realize they got a placebo often feel disappointed, which muddies the data. It becomes nearly impossible to separate a drug's real effects from the power of expectation.
So why bother trying? Because, Woolley says, medicine has been fooled by obvious effects before. Heart stents for stable chest pain and knee surgery for arthritis both looked like miracles — until carefully controlled "sham" trials revealed they weren't. "We're excited about this paper because it outlines a novel approach that might finally make effective masking possible for psychedelics," he said.
The proposal is called UMBRAA, short for Unidentifiable Multidrug Blinding with Reduced, Authorized Awareness. The idea: instead of using a simple active placebo like niacin (which causes flushing but little else), researchers would design clever combinations of FDA-approved drugs — perhaps a sedative, a stimulant and a cannabinoid together. The mix of effects could create a strange, intense altered state that's much harder to tell apart from psilocybin, the compound in "magic" mushrooms.
UMBRAA also suggests telling participants less about exactly what they might receive, so it's harder to guess which treatment they got. The researchers are candid that this raises safety and ethical questions, and any future trial would need careful screening, close medical monitoring and strong regulatory oversight.
The stakes are high. Millions of people with depression, anxiety and other serious mental illnesses do not respond to existing treatments, which is why psychedelics have drawn so much interest. But the authors argue that if researchers accept failed masking as unavoidable, these compounds will never be rigorously tested — and patients could be offered treatments that only seem to work.
UMBRAA is a proposal, not a proven method, Woolley stresses. The next steps are to find safe drug combinations, test whether they actually improve masking, and build in proper safeguards. If it works, it could give doctors something rare: reliable answers about which brain-changing medicines truly heal — and which ones just look like they do.